Proud to be involved in health technology assessments (HTAs)
Lymphoma Action ensure that the patient voice is heard at HTAs, resulting in better access to the latest treatments.
News
Research and clinical trials
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
Encouraging results for new treatments in DLBCL
Tafasitamab plus lenalidomide show promise for people with relapsed or refractory DLBCL who are not suitable for a stem cell transplant.
Promising results for new oral treatment in DLBCL
Selinexor shows early potential for people with relapsed or refractory DLBCL who have had at least two previous courses of treatment.
Highlights from ASCO
The American Society of Clinical Oncology (ASCO) held a virtual conference at the end of May.
Promising results for acalabrutinib in chronic lymphocytic leukaemia (CLL)
Acalabrutinib shows potential as a chemotherapy-free treatment option for people with CLL who have not been treated before.
Positive early results for CAR T-cell therapy in mantle cell lymphoma
Clinical trial results published.
Promising results for cancer screening blood test
A new blood test has been developed that could be used to screen for more than 50 types of cancer, including lymphoma.
Encouraging trial results for relapsed or refractory DLBCL
Results of the LEGEND trial of a lenalidomide-based regimen in DLBCL have been published in the Annals of Haematology.
People with low-risk, high-grade B-cell lymphoma may need fewer cycles of chemotherapy
The FLYER study found that four cycles of R-CHOP was no less effective than six cycles in people with stage 1 or 2 high-grade B-cell lymphoma and no risk factors.
Acalabrutinib shows promise in Waldenström’s macroglobulinaemia
Phase 2 trial finds that acalabrutinib is active and well tolerated in people with Waldenström’s macroglobulinaemia